Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00323791 | Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | terminated | Phase 2 | 100 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | terminated | Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Apr 10, 2009 |
| clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | terminated | Phase 2 | 36 | AttenuonINDUSTRY | 1 | Dec 6, 2007 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2009source: clinicaltrials